Aptuit has formed a strategic partnership with Dimension Therapeutics, a Cambridge, Massachusetts-based biopharmaceutical company, to advance late preclinical-stage studies for select rare disease programs. The partnership has already initiated three integrated development projects.

Aptuit supports compounds using molecular and cellular biology and also supports investigational new drug (IND) programs. Dimension Therapeutics is advancing novel adeno-associated virus gene therapies targeting rare diseases associated with the liver. The alliance with Aptuit will allow it to select priority preclinical programs to progress to the IND stage through the leveraging of their joint expertise.

Source: Aptuit